Shamburg News · 8-K filed Nov 12, 2026, 7:00 AM EST

Traws Pharma Reports Final Phase 2a Ratutrelvir Results and Completes Tivoxavir Marboxil Bridging Study

TRAW · Traws Pharma, Inc.

  • Other event
  • Reg FD disclosure
  • Materiality: medium

On November 12, 2026, Traws Pharma, Inc. issued a press release reporting final results of its 92-patient Phase 2a study of ratutrelvir for mild-to-moderate COVID-19, which showed a median time to sustained symptom resolution of 13.5 days versus 14.5 days for PAXLOVID in PAXLOVID-eligible patients, with no viral rebound through Day 28. The company also reported completion of a healthy volunteer bridging study of a compressed tablet formulation of tivoxavir marboxil and a toxicology retest, with regulatory resubmission planned for the fourth quarter of 2026. Traws intends to discuss a registration path for PAXLOVID-ineligible patients with the FDA. The information is furnished under Item 7.01 and not deemed filed.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-125797.

Written from the filing by Shamburg Markets. Figures are as reported by the company.